Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES
Cancer. 2013 119 (10): 1776-83

PMID: 23436342 · PMCID: PMC3939707 · DOI:10.1002/cncr.27995

MeSH Terms (24)

Adult Aged Analysis of Variance Antineoplastic Combined Chemotherapy Protocols Biomarkers, Tumor Breast Neoplasms Carcinoma, Ductal, Breast Carcinoma, Lobular Female Humans Immunohistochemistry Induction Chemotherapy Magnetic Resonance Imaging Middle Aged Neoadjuvant Therapy Neoplasm Grading Neoplasm Staging Predictive Value of Tests Receptor, ErbB-2 Receptors, Estrogen Receptors, Progesterone Retrospective Studies Sensitivity and Specificity Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: